Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC197 universal CAR-T in relapsed or refractory CD19-positive B-cell malignancies
ISRCTN11885863Phase 2Completed
- Sponsor
- Gracell Biotechnologies
- Start
- Feb 2020
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of GC197 in B cell acute lymphoblastic leukemia (B-ALL) and B lymphoblastic lymphoma (B-LL), sponsored by Gracell Biotechnologies. Primary endpoints: Dose-limiting toxicity and Overall response rate. Started Feb 2020; status: completed.
02
Drugs
GC197
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)B lymphoblastic lymphoma (B-LL)
Beyond the preview
Go deeper on ISRCTN11885863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN11885863.